Asset Management One Co. Ltd. Sells 822 Shares of United Therapeutics Corporation $UTHR

Asset Management One Co. Ltd. trimmed its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 3.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,051 shares of the biotechnology company’s stock after selling 822 shares during the period. Asset Management One Co. Ltd. owned 0.06% of United Therapeutics worth $7,198,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Chung Wu Investment Group LLC bought a new stake in shares of United Therapeutics during the 2nd quarter valued at $29,000. SVB Wealth LLC purchased a new position in United Therapeutics during the first quarter valued at $32,000. Geneos Wealth Management Inc. grew its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares in the last quarter. Brooklyn Investment Group grew its stake in United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 98 shares in the last quarter. Finally, WPG Advisers LLC purchased a new position in United Therapeutics during the first quarter valued at $60,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several research analyst reports. Bank of America raised their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, September 5th. UBS Group raised their target price on shares of United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of United Therapeutics in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada began coverage on shares of United Therapeutics in a research note on Friday, September 26th. They set an “outperform” rating and a $569.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $461.62.

United Therapeutics Trading Up 0.6%

United Therapeutics stock opened at $421.04 on Tuesday. The firm has a 50-day moving average price of $399.53 and a 200-day moving average price of $333.88. The firm has a market capitalization of $18.99 billion, a PE ratio of 16.43, a price-to-earnings-growth ratio of 4.56 and a beta of 0.66. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $459.48.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.United Therapeutics’s revenue was up 11.7% compared to the same quarter last year. During the same quarter last year, the business posted $5.85 EPS. As a group, sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $427.41, for a total value of $9,616,725.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 4,000 shares of the business’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $424.06, for a total transaction of $1,696,240.00. Following the completion of the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at approximately $55,127.80. This trade represents a 96.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 326,935 shares of company stock valued at $135,057,522 in the last three months. Company insiders own 10.30% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.